Repositioning Candidate Details
| Candidate ID: | R1007 |
| Source ID: | DB06413 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Armodafinil |
| Synonyms: | (–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide; (−)-(R)-modafinil; (−)-modafinil; (R)-(−)-modafinil; (R)-modafinil |
| Molecular Formula: | C15H15NO2S |
| SMILES: | NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007. |
| CAS Number: | 112111-43-0 |
| Molecular Weight: | 273.35 |
| DrugBank Indication: | Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Nuvigil (armodafinil) is a single-isomer of modafini. The exact mechanism of action is unknown. Armodafinil belongs to a class of drugs known as eugeroics, which are stimulants that provide long-lasting mental arousal. Pharmacologically, armodafinil does not bind to or inhibit several receptors and enzymes potentially relevant for sleep/wake regulation. Armodafinil is not a direct- or indirect-acting dopamine receptor agonist. However, in vitro, both armodafinil and modafinil bind to the dopamine transporter and inhibit dopamine reuptake. |
| Targets: | Sodium-dependent dopamine transporter antagonist&inhibitor |
| Inclusion Criteria: | Indication associated |
